Abstract
Influenza A virus poses a direct threat to humans and results in the deaths of about 36,000 people each year in USA. There is tremendous concern that highly virulent variants of the virus may emerge and cause a major pandemic. The influenza virus attacks the respiratory tracts and may cause acute lung inflammation. Certain evidence suggests that the lethal effect of the influenza virus results from inflammation of the host lung rather than from direct viral cytopathy. This has led to the concept that co-administration of effective antiviral agents with inflammation attenuators, by which a reduction, but not an elimination of inflammation would improve lung function without compromising virus clearance, and might result in a better treatment outcome of virulent influenza. Anti-inflammatory antibodies are widely developed for treatment of inflammatory diseases such as Crohns disease, ulcerative colitis, rheumatoid arthritis, psoriasis and so on. This review focuses on anti-inflammatory antibodies and discusses the feasibility and prospects for using them to attenuate the host inflammatory responses in the lung for the treatment and disease management of virulent influenza.
Keywords: Anti-inflammatory antibodies, inflammation attenuators, influenza A virus, treatment and disease management of virulent influenza
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Feasibility and Prospects for Anti-Inflammatory Antibodies in the Treatment and Disease Management of Influenza
Volume: 7 Issue: 2
Author(s): Wei-Gang Hu and Jonathan P. Wong
Affiliation:
Keywords: Anti-inflammatory antibodies, inflammation attenuators, influenza A virus, treatment and disease management of virulent influenza
Abstract: Influenza A virus poses a direct threat to humans and results in the deaths of about 36,000 people each year in USA. There is tremendous concern that highly virulent variants of the virus may emerge and cause a major pandemic. The influenza virus attacks the respiratory tracts and may cause acute lung inflammation. Certain evidence suggests that the lethal effect of the influenza virus results from inflammation of the host lung rather than from direct viral cytopathy. This has led to the concept that co-administration of effective antiviral agents with inflammation attenuators, by which a reduction, but not an elimination of inflammation would improve lung function without compromising virus clearance, and might result in a better treatment outcome of virulent influenza. Anti-inflammatory antibodies are widely developed for treatment of inflammatory diseases such as Crohns disease, ulcerative colitis, rheumatoid arthritis, psoriasis and so on. This review focuses on anti-inflammatory antibodies and discusses the feasibility and prospects for using them to attenuate the host inflammatory responses in the lung for the treatment and disease management of virulent influenza.
Export Options
About this article
Cite this article as:
Hu Wei-Gang and Wong P. Jonathan, Feasibility and Prospects for Anti-Inflammatory Antibodies in the Treatment and Disease Management of Influenza, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2008; 7 (2) . https://dx.doi.org/10.2174/187152308784533212
DOI https://dx.doi.org/10.2174/187152308784533212 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Advances in the Field of Calcium Channel Antagonists: Cardiovascular Effects and Structure-Activity Relationships
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Capturing and Amplifying Impurities from Recombinant Therapeutic Proteins Via Combinatorial Peptide Libraries: A Proteomic Approach
Current Pharmaceutical Biotechnology Chronotherapeutic Drug Delivery Systems - An Approach to Circadian Rhythms Diseases
Current Drug Delivery Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors
Mini-Reviews in Medicinal Chemistry Topical Analgesic Nanolipid Vesicles Formulation of Capsaicinoids Extract of Bhut Jolokia (Capsicum chinense Jacq): Pharmacodynamic Evaluation in Rat Models and Acceptability studies in Human Volunteers
Current Drug Delivery Anti-Tumor Necrosis Factor-α Therapy in Undifferentiated Spondyloarthritis (USpA)
Current Rheumatology Reviews Current Biological Therapies for Inflammatory Bowel Disease
Current Pharmaceutical Design Lactoferrin as a Natural Immune Modulator
Current Pharmaceutical Design Interaction Between Arsenic Trioxide and Human Primary Cells: Emphasis on Human Cells of Myeloid Origin
Inflammation & Allergy - Drug Targets (Discontinued) Anti-inflammatory Sulfur-Containing Agents with Additional Modes of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry CCR1 and CCR2 Antagonists
Current Topics in Medicinal Chemistry Involvement of Orbital Structures in Rheumatic Disease
Current Rheumatology Reviews A More Radical Solution
Reviews on Recent Clinical Trials Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Induced Dyspepsia
Current Pharmaceutical Design Synthesis, Characterization, Biological Activity and Voltammetric Behavior and Determination of Cefaclor Metal Complexes
Current Analytical Chemistry CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry The Relationship Between Social Support, Social Constraint, and Psychological Adjustment for Patients with Rare Autoimmune Disease
Current Rheumatology Reviews Microparticles in Health and Disease: Small Mediators, Large Role?
Current Vascular Pharmacology Bridged Piperazines and Piperidines as CCR1 Antagonists with Oral Activity in Models of Arthritis and Multiple Sclerosis
Letters in Drug Design & Discovery Structural Comparison of p38 Inhibitor-Protein Complexes: A Review of Recent p38 Inhibitors Having Unique Binding Interactions
Current Topics in Medicinal Chemistry